News | August 08, 2022
Rossari Biotech Q1 FY23 revenue up 88%; Profit up 17%
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
Lupin is the 6th largest company in the Indian Pharmaceutical Market
The company has reported total income of Rs. 253.42 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 128.79 crores during the period ended June 30, 2022.
he company has reported total income of Rs. 5478.62 crores during the period ended June 30, 2022.
Torrent Pharmaceuticals has reported total income of Rs. 2377 crores during the period ended June 30, 2022.
GMM Pfaudler has reported total income of Rs. 767.73 crores during the period ended June 30, 2022
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
